TruScreen Group Limited

Equities

TRU

NZTRUE0001S7

Advanced Medical Equipment & Technology

End-of-day quote New Zealand S.E. Other stock markets 06:00:00 2024-05-20 pm EDT			5-day change	1st Jan Change
0.02 ^NZD	+5.26%		+17.65%	-13.04%

Mar. 13	Truscreen Group Raises Additional NZ$520,000 via Share Placement; Shares Jump 5%	MT
Mar. 08	New Zealand Shares Jump on Friday, Fisher & Paykel Healthcare's Chair to Retire	MT

TruScreen Group Limited Announces Clinical Evaluation Results from Saudi Arabia

March 13, 2023 at 05:16 pm EDT

TruScreen Group Limited announced that the private medical services provider, Dr. Sulaiman Al-Habib Medical Group (DSAMG), has recently completed the analysis of results from its cervical screening clinical evaluation of TruScreen Ultra and Liquid Based Cytology (LBC). A cohort of 507 women were examined with TruScreen and LBC across multiple medical centres of DSAMG. The preliminary results confirmed that TruScreen's sensitivity was 83.3% (LBC: 66%) and specificity was 95% (LBC 98%).

Latest news about TruScreen Group Limited

Truscreen Group Raises Additional NZ$520,000 via Share Placement; Shares Jump 5%	Mar. 12	MT
New Zealand Shares Jump on Friday, Fisher & Paykel Healthcare's Chair to Retire	Mar. 07	MT
TruScreen to Start Clinical Evaluation Trials for Cancer Screening Device	Mar. 07	MT
Truscreen Close to Raising NZ$500,000	Mar. 04	MT
New Zealand Shares Close the Week in the Green; Port of Tauranga’s Fiscal H1 Revenue Falls	Feb. 22	MT
Truscreen's CEO Resigns	Feb. 22	MT
TruScreen Group Limited Announces CEO Changes	Feb. 22	CI
Truscreen Group to Offer Pro-Rata Renounceable Rights Issue; Shares Plunge 11%	Feb. 11	MT
TruScreen Secures Reimbursement Approval in Saudi Arabia for Cervical Cancer Screening Device; Shares Rise 4%	Feb. 11	MT
Truscreen Secures Regulatory Approval to Expand Use of Cancer Screening Device in Mexico; Shares Rise 4%	Feb. 06	MT
Truscreen Group Limited Receives Approval in Mexico to Enter Public Health Sector	Feb. 06	CI
TruScreen's Nine-Month Revenue Surges 34%	Jan. 25	MT
Truscreen Group Limited Announces Sales Results for the Nine Months Ended 31 December 2023	Jan. 24	CI
New Zealand Bourse Regulator Slaps TruScreen a Fine on Audit Committee Breach	Jan. 02	MT
TruScreen Wins Polish Start-Up Challenge; Shares Rise 5%	Dec. 13	MT
New Zealand Shares Rebound on Wednesday, Air New Zealand Expects Fiscal H1 Earnings to be on the Lower End of Guidance	Dec. 12	MT
TruScreen's Diagnostic Device Lands Spot in Vietnam Health Ministry's Approved Technical List; Shares Rise 5%	Dec. 12	MT
TruScreen Secures Purchase Order from Zimbabwe	Nov. 05	MT
TruScreen Group Limited Confirms Receipt of Further Purchase Order from Zimbabwe for SUS	Nov. 05	CI
TruScreen Group Limited Reports Earnings Results for the Half Year Ended September 30, 2023	Nov. 05	CI
Truscreen Logs 33% Growth in Fiscal H1 Revenue	23-10-12	MT
TruScreen Group Limited Announces Sales Results for the First Half of 2024	23-10-11	CI
Middle Eastern Hospital Network Adopts TruSreen’s Cervical Cancer Screening Device in Saudi Arabia	23-09-18	MT
TruScreen Group Limited Announces Dr Sulaiman Al-Habib Medical Group Installs First Tranche of Four TruScreen Devices for Commercial Use, for Screening of Cervical Cancer in Saudi Arabia	23-09-17	CI
TruScreen Group Limited Reports Sales Results for the First Quarter Ended June 2023	23-08-14	CI

Chart TruScreen Group Limited

Duration

Period

More charts

Company Profile

Truscreen Group Limited is a New Zealand-based medical device company. The Company is engaged in the development of an artificial intelligence (AI)-enabled device that can detect precancerous and cancerous cervical changes in real-time via optical and electrical measurements of cervical tissue. The Companyâs cervical screening technology resolves ongoing issues with cytology, including failed samples, poor patient follow-up, patient discomfort, and the need for supporting laboratory infrastructure. The TruScreen device uses opto-electrical technology to evaluate the tissue of the cervix. The TruScreen device consists of a disposable Single Use Sensor (SUS), a Handheld Device (HHD), and an Intelligent Cradle (IC) which works together to detect and identify cancerous and precancerous changes to the cervix. It also resolves the problems associated with human papillomavirus (HPV) testing, which tests for the much more prevalent HPV virus.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-05-28 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
TRUSCREEN GROUP LIMITED	-13.04%	6.42M
THERMO FISHER SCIENTIFIC	+10.52%	227B
DANAHER CORPORATION	+15.22%	198B
INTUITIVE SURGICAL, INC.	+18.35%	142B
BOSTON SCIENTIFIC CORPORATION	+31.01%	111B
SIEMENS HEALTHINEERS AG	+1.56%	64.16B
EDWARDS LIFESCIENCES CORPORATION	+18.39%	54.1B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+5.12%	51.41B
AGILENT TECHNOLOGIES, INC.	+11.08%	45.32B
GE HEALTHCARE TECHNOLOGIES INC.	+5.50%	37.32B

Other Advanced Medical Equipment & Technology